Global Pharmaceutical Growth.
Advanov Pharma is a fully integrated pharmaceutical company specialized in development, regulatory structuring, and international commercialization of high-value products across regulated and semi-regulated markets.
Global Presence
35+ countries
Regulatory Excellence
EU, LATAM, SEA markets
Advanced Portfolio
High-barrier generics & VAFs
Strategic Partnerships
Global & regional leaders
Quality Assured
EU-GMP certified
Advanov develops and commercializes high-barrier products across key therapeutic areas — powered by advanced technology and global quality standards.
Advanced injectables for targeted and chemotherapy treatments.
High-value sterile injectables for acute and critical settings.
Broad-spectrum formulations combating resistant infections globally.
Differentiated products for regulated cardiovascular markets.
Precision CNS formulations for complex therapeutic needs.
Specialized GI formulations for emerging and regulated markets.
High-barrier hormonal injectables with complex regulatory dossiers.
Safe, innovative devices for critical care and patient safety.
End-to-end development from molecule selection to global commercialization.
Dossier strategy across 50+ regulatory authorities worldwide.
Operating across LATAM, Africa, CIS, SEA and European markets.
Go-to-market execution, brand building and sustainable growth.
Advanov Pharma is a fully integrated pharmaceutical company with end-to-end ownership across the product lifecycle — transforming selected molecules into commercially viable, regulatory-compliant and globally scalable pharmaceutical assets.
Science-Led Product Selection & End-to-End Development
Regulatory-First Strategy Across 50+ Authorities Worldwide
EU-GMP & PIC/S Compliant Manufacturing Network
Commercial Expansion Across LATAM, Africa, CIS & SEA
